Skip to content

Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00324311
Enrollment
182
Registered
2006-05-11
Start date
2005-12-31
Completion date
2010-02-28
Last updated
2011-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn

Brief summary

Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed debridement. The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications. The objective of this study is to evaluate the safety and enzymatic debriding efficacy of Debrase Gel Dressing (DGD) in hospitalized patients with deep partial thickness and/or full thickness thermal burns and to compare DGD to standard of care (SOC).

Detailed description

Completed study.

Interventions

DRUGDGD

Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.

Sponsors

MediWound Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. Males and females between 4 years to 55 years of age, 2. Thermal burns caused by fire/flame, scalds or contact, 3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5% and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive study treatment, 4. At least one wound of ≥ 2% TBSA deep partial thickness and/or full thickness burn, 5. Total burn wounds ≤ 30% TBSA, 6. Signed written informed consent.

Exclusion criteria

1. Deep partial thickness and/or full thickness facial burn wounds, \> 0.5% TBSA; study treatment of facial burns is not allowed, 2. Study treatment of perineal and/or genital burns (A patient with these wounds may be enrolled but the wounds may not be designated as target wounds), 3. Circumferential anterior/posterior trunk full thickness fire/flame burns, \> 15% TBSA, (Circumferential is defined as encircling ≥ 80% of the trunk circumference.) 4. Pre-enrollment escharotomy, 5. Heavily contaminated burns or pre-existing infections, 6. Signs that may indicate smoke inhalation, 7. General condition of patient would contraindicate surgery, 8. Pregnant women (positive pregnancy test) or nursing mothers, 9. Poorly controlled diabetes mellitus (HbA1c\>9%), 10. Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension, COPD or pre-existing oxygen-dependent pulmonary diseases), 11. Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema, surgery to the regional lymph nodes, obesity, varicose veins), 12. Immediate life threatening conditions (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or neoplastic disease),

Design outcomes

Primary

MeasureTime frame
Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial woundsSurgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups)
Co-primary: % treated wound autografted of deep partial woundsPost-debridement autografts

Secondary

MeasureTime frame
% treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, for all woundsAs for primary endpoint
Time to complete wound closure% epithelialization assessed post-debridement at weekly intervals until all a patient's wounds closed
Timely eschar removalDebridement procedures
Blood lossThroughout study

Countries

Australia, Brazil, France, Germany, Israel, Italy, Poland, Romania, Slovakia, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026